Loading
Life sciences · Journal article
Journal of Nuclear Medicine · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
We characterized patterns of treatment response and progression during [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) using serial posttreatment SPECT/CT and prostate-specific membrane antigen (PSMA) PET imaging and evaluated cycle-by-cycle prostate-specific antigen (PSA)–imaging concordance. Methods: We retrospectively analyzed 361 patients from 2 academic centers who received at least 2 cycles of [177Lu]Lu-PSMA RPT between May 2017 and March 2025. Posttreatment SPECT/CT scans were qualitatively evaluated to determine the site and pattern of response and progression, including PSMA low-avidity and PSMA-negative disease. Progression was defined by the appearance of new lesions or at least a 2-fold growth in preexisting lesions on SPECT/CT. PSA response was defined per Prostate Cancer Clinical Trials Working Group 3 criteria as at least a 50% decline from baseline. For cycle-by-cycle concordance analysis, PSA change was classified directionally as rising or falling relative to the prior cycle. In patients who paused or completed RPT after response, progression imaging was compared with the final on-treatment SPECT/CT scan. Results: Overall, 290 of 361 (80%) patients demonstrated a decrease in lesion size or number on posttreatment imaging. Of 312 patients with baseline bone disease, 81% demonstrated a response on posttreatment imaging. In total, 156 of 361 patients (43%) demonstrated progression during treatment. New osseous lesions developed in 132 patients, of whom 89 (67%) had PSMA low-avidity disease. At cycle 2, 64% of new lesions were osseous, increasing to at least 90% by cycles 4–6. PSMA-negative progression occurred in 22 patients (6%), predominantly in the liver (n = 11) and lymph nodes (n = 8), with 59% detected at cycle 2. Among 81 patients with imaging available at PSA progression after treatment completion or pause, 74 (91%) had imaging progression; of these, 69 (93%) demonstrated osseous and 13 (18%) nodal progression. PSA and imaging were discordant in 25%–43% of patients across cycles, with discordance increasing from cycle 2 to cycle 6. Conclusion: Progression during [177Lu]Lu-PSMA RPT occurs most frequently in bone, with 67% of patients with new osseous lesions demonstrating a PSMA low-avidity disease component. PSMA-negative progression is uncommon and tends to emerge early. PSA–imaging discordance is frequent, underscoring the need for integrated imaging assessment throughout treatment.